Hitech Windlass, Managing Director of Windlass Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.How to protect and exponentially Grow your investment portfolio during economic boom or bust, How learn stock market, How to earn money in stock market,earn money from home .
IPO-bound Windlass Biotech plans to build CDMO injectable biz, trade generics
Hitech Windlass, Managing Director of Windlass Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.
Subscribe to:
Post Comments (Atom)
-
Market-men said the fall in gold prices at futures trade was mostly due to trimming of positions by participants.
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
No comments:
Post a Comment